Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 669

1.

Endocannabinoid System and the Kidneys: From Renal Physiology to Injury and Disease.

Chua JT, Argueta DA, DiPatrizio NV, Kovesdy CP, Vaziri ND, Kalantar-Zadeh K, Moradi H.

Cannabis Cannabinoid Res. 2019 Mar 13;4(1):10-20. doi: 10.1089/can.2018.0060. eCollection 2019. Review.

2.

Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations.

Rostoker G, Vaziri ND.

Heliyon. 2019 Jul 12;5(7):e02045. doi: 10.1016/j.heliyon.2019.e02045. eCollection 2019 Jul. Review.

3.

Natural products against renin-angiotensin system for antifibrosis therapy.

Yang T, Chen YY, Liu JR, Zhao H, Vaziri ND, Guo Y, Zhao YY.

Eur J Med Chem. 2019 Jun 29;179:623-633. doi: 10.1016/j.ejmech.2019.06.091. [Epub ahead of print] Review.

PMID:
31279295
4.

Small molecules from natural products targeting the Wnt/β-catenin pathway as a therapeutic strategy.

Liu D, Chen L, Zhao H, Vaziri ND, Ma SC, Zhao YY.

Biomed Pharmacother. 2019 Sep;117:108990. doi: 10.1016/j.biopha.2019.108990. Epub 2019 Jun 19. Review.

5.

Redox signaling in aging kidney and opportunity for therapeutic intervention through natural products.

Chen YY, Yu XY, Chen L, Vaziri ND, Ma SC, Zhao YY.

Free Radic Biol Med. 2019 Jun 11;141:141-149. doi: 10.1016/j.freeradbiomed.2019.06.012. [Epub ahead of print] Review.

PMID:
31199964
6.

Microbiome-metabolomics reveals gut microbiota associated with glycine-conjugated metabolites and polyamine metabolism in chronic kidney disease.

Feng YL, Cao G, Chen DQ, Vaziri ND, Chen L, Zhang J, Wang M, Guo Y, Zhao YY.

Cell Mol Life Sci. 2019 May 30. doi: 10.1007/s00018-019-03155-9. [Epub ahead of print]

PMID:
31147751
7.

Small molecule inhibitors of epithelial-mesenchymal transition for the treatment of cancer and fibrosis.

Feng YL, Chen DQ, Vaziri ND, Guo Y, Zhao YY.

Med Res Rev. 2019 May 27. doi: 10.1002/med.21596. [Epub ahead of print] Review.

PMID:
31131921
8.

Activated NF-κB/Nrf2 and Wnt/β-catenin pathways are associated with lipid metabolism in CKD patients with microalbuminuria and macroalbuminuria.

Feng YL, Chen H, Chen DQ, Vaziri ND, Su W, Ma SX, Shang YQ, Mao JR, Yu XY, Zhang L, Guo Y, Zhao YY.

Biochim Biophys Acta Mol Basis Dis. 2019 Sep 1;1865(9):2317-2332. doi: 10.1016/j.bbadis.2019.05.010. Epub 2019 May 16.

PMID:
31102786
9.

Chronic Kidney Disease Increases Cerebral Microbleeds in Mouse and Man.

Lau WL, Nunes ACF, Vasilevko V, Floriolli D, Lertpanit L, Savoj J, Bangash M, Yao Z, Shah K, Naqvi S, Paganini-Hill A, Vaziri ND, Cribbs DH, Fisher M.

Transl Stroke Res. 2019 May 4. doi: 10.1007/s12975-019-00698-8. [Epub ahead of print]

PMID:
31055735
10.

Ferric Citrate Attenuates Cardiac Hypertrophy and Fibrosis in a Rat Model of Chronic Kidney Disease.

Goto M, Suematsu Y, Nunes ACF, Jing W, Khazaeli M, Lau WL, Vaziri ND.

Iran J Kidney Dis. 2019 Mar;13(2):98-104.

11.

Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan.

Chen DQ, Cao G, Chen H, Argyopoulos CP, Yu H, Su W, Chen L, Samuels DC, Zhuang S, Bayliss GP, Zhao S, Yu XY, Vaziri ND, Wang M, Liu D, Mao JR, Ma SX, Zhao J, Zhang Y, Shang YQ, Kang H, Ye F, Cheng XH, Li XR, Zhang L, Meng MX, Guo Y, Zhao YY.

Nat Commun. 2019 Apr 1;10(1):1476. doi: 10.1038/s41467-019-09329-0.

12.

The Matrix Metalloproteinase-13 Inhibitor Poricoic Acid ZI Ameliorates Renal Fibrosis by Mitigating Epithelial-Mesenchymal Transition.

Chen L, Cao G, Wang M, Feng YL, Chen DQ, Vaziri ND, Zhuang S, Zhao YY.

Mol Nutr Food Res. 2019 Mar 29:e1900132. doi: 10.1002/mnfr.201900132. [Epub ahead of print]

PMID:
30925007
13.

Amylose resistant starch (HAM-RS2) supplementation increases the proportion of Faecalibacterium bacteria in end-stage renal disease patients: Microbial analysis from a randomized placebo-controlled trial.

Laffin MR, Tayebi Khosroshahi H, Park H, Laffin LJ, Madsen K, Kafil HS, Abedi B, Shiralizadeh S, Vaziri ND.

Hemodial Int. 2019 Jul;23(3):343-347. doi: 10.1111/hdi.12753. Epub 2019 Mar 29.

PMID:
30924310
14.

Association of Serum Paraoxonase/Arylesterase Activity with All-Cause Mortality in Maintenance Hemodialysis Patients.

Suematsu Y, Goto M, Park C, Nunes ACF, Jing W, Streja E, Rhee CM, Cruz S, Kashyap ML, Vaziri ND, Narayanaswami V, Kalantar-Zadeh K, Moradi H.

J Clin Endocrinol Metab. 2019 Mar 28. pii: jc.2019-00334. doi: 10.1210/jc.2019-00334. [Epub ahead of print]

PMID:
30920627
15.

Gut microbial short-chain fatty acids and the risk of diabetes.

Lau WL, Vaziri ND.

Nat Rev Nephrol. 2019 Jul;15(7):389-390. doi: 10.1038/s41581-019-0142-7. No abstract available.

PMID:
30918350
16.

Unilateral ureteral obstruction causes gut microbial dysbiosis and metabolome disorders contributing to tubulointerstitial fibrosis.

Chen L, Chen DQ, Liu JR, Zhang J, Vaziri ND, Zhuang S, Chen H, Feng YL, Guo Y, Zhao YY.

Exp Mol Med. 2019 Mar 27;51(3):38. doi: 10.1038/s12276-019-0234-2.

17.

Impact of Gut Dysbiosis on Neurohormonal Pathways in Chronic Kidney Disease.

Jazani NH, Savoj J, Lustgarten M, Lau WL, Vaziri ND.

Diseases. 2019 Feb 13;7(1). pii: E21. doi: 10.3390/diseases7010021. Review.

18.

Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNFκB/Nrf2 axis.

Chen DQ, Feng YL, Chen L, Liu JR, Wang M, Vaziri ND, Zhao YY.

Free Radic Biol Med. 2019 Apr;134:484-497. doi: 10.1016/j.freeradbiomed.2019.01.046. Epub 2019 Feb 2.

PMID:
30716432
19.

Metaproteomics reveals potential mechanisms by which dietary resistant starch supplementation attenuates chronic kidney disease progression in rats.

Zybailov BL, Glazko GV, Rahmatallah Y, Andreyev DS, McElroy T, Karaduta O, Byrum SD, Orr L, Tackett AJ, Mackintosh SG, Edmondson RD, Kieffer DA, Martin RJ, Adams SH, Vaziri ND, Arthur JM.

PLoS One. 2019 Jan 30;14(1):e0199274. doi: 10.1371/journal.pone.0199274. eCollection 2019.

20.

Microbiome-metabolome reveals the contribution of gut-kidney axis on kidney disease.

Chen YY, Chen DQ, Chen L, Liu JR, Vaziri ND, Guo Y, Zhao YY.

J Transl Med. 2019 Jan 3;17(1):5. doi: 10.1186/s12967-018-1756-4. Review.

21.

Gut microbiota and inflammation in chronic kidney disease and their roles in the development of cardiovascular disease.

Onal EM, Afsar B, Covic A, Vaziri ND, Kanbay M.

Hypertens Res. 2019 Feb;42(2):123-140. doi: 10.1038/s41440-018-0144-z. Epub 2018 Nov 30. Review.

PMID:
30504819
22.

The Phosphate Binder Ferric Citrate Alters the Gut Microbiome in Rats with Chronic Kidney Disease.

Lau WL, Vaziri ND, Nunes ACF, Comeau AM, Langille MGI, England W, Khazaeli M, Suematsu Y, Phan J, Whiteson K.

J Pharmacol Exp Ther. 2018 Dec;367(3):452-460. doi: 10.1124/jpet.118.251389. Epub 2018 Oct 4.

23.
24.

Phosphate Binder, Ferric Citrate, Attenuates Anemia, Renal Dysfunction, Oxidative Stress, Inflammation, and Fibrosis in 5/6 Nephrectomized CKD Rats.

Jing W, Nunes ACF, Farzaneh T, Khazaeli M, Lau WL, Vaziri ND.

J Pharmacol Exp Ther. 2018 Oct;367(1):129-137. doi: 10.1124/jpet.118.249961. Epub 2018 Aug 9.

PMID:
30093458
25.

New insights into TGF-β/Smad signaling in tissue fibrosis.

Hu HH, Chen DQ, Wang YN, Feng YL, Cao G, Vaziri ND, Zhao YY.

Chem Biol Interact. 2018 Aug 25;292:76-83. doi: 10.1016/j.cbi.2018.07.008. Epub 2018 Jul 11. Review.

PMID:
30017632
26.

Inverse Association Between Serum Non-High-Density Lipoprotein Cholesterol Levels and Mortality in Patients Undergoing Incident Hemodialysis.

Chang TI, Streja E, Ko GJ, Naderi N, Rhee CM, Kovesdy CP, Kashyap ML, Vaziri ND, Kalantar-Zadeh K, Moradi H.

J Am Heart Assoc. 2018 Jun 9;7(12). pii: e009096. doi: 10.1161/JAHA.118.009096.

27.

The crosstalk of gut microbiota and chronic kidney disease: role of inflammation, proteinuria, hypertension, and diabetes mellitus.

Kanbay M, Onal EM, Afsar B, Dagel T, Yerlikaya A, Covic A, Vaziri ND.

Int Urol Nephrol. 2018 Aug;50(8):1453-1466. doi: 10.1007/s11255-018-1873-2. Epub 2018 May 4. Review.

PMID:
29728993
28.

Divergent antioxidant capacity of human islet cell subsets: A potential cause of beta-cell vulnerability in diabetes and islet transplantation.

Miki A, Ricordi C, Sakuma Y, Yamamoto T, Misawa R, Mita A, Molano RD, Vaziri ND, Pileggi A, Ichii H.

PLoS One. 2018 May 3;13(5):e0196570. doi: 10.1371/journal.pone.0196570. eCollection 2018.

29.

ESRD-induced dyslipidemia-Should management of lipid disorders differ in dialysis patients?

Moradi H, Streja E, Vaziri ND.

Semin Dial. 2018 Jul;31(4):398-405. doi: 10.1111/sdi.12706. Epub 2018 Apr 29. Review.

30.

Novel inhibitors of the cellular renin-angiotensin system components, poricoic acids, target Smad3 phosphorylation and Wnt/β-catenin pathway against renal fibrosis.

Wang M, Chen DQ, Chen L, Cao G, Zhao H, Liu D, Vaziri ND, Guo Y, Zhao YY.

Br J Pharmacol. 2018 Jul;175(13):2689-2708. doi: 10.1111/bph.14333. Epub 2018 May 22.

31.

Effect of high amylose resistant starch (HAM-RS2) supplementation on biomarkers of inflammation and oxidative stress in hemodialysis patients: a randomized clinical trial.

Tayebi Khosroshahi H, Vaziri ND, Abedi B, Asl BH, Ghojazadeh M, Jing W, Vatankhah AM.

Hemodial Int. 2018 Oct;22(4):492-500. doi: 10.1111/hdi.12653. Epub 2018 Mar 13.

PMID:
29532981
32.

Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins.

Lau WL, Savoj J, Nakata MB, Vaziri ND.

Clin Sci (Lond). 2018 Mar 9;132(5):509-522. doi: 10.1042/CS20171107. Print 2018 Mar 15. Review.

33.

Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment.

Chen L, Yang T, Lu DW, Zhao H, Feng YL, Chen H, Chen DQ, Vaziri ND, Zhao YY.

Biomed Pharmacother. 2018 May;101:670-681. doi: 10.1016/j.biopha.2018.02.090. Epub 2018 Mar 22. Review.

PMID:
29518614
34.

Dietary tetrahydrocurcumin reduces renal fibrosis and cardiac hypertrophy in 5/6 nephrectomized rats.

Lau WL, Khazaeli M, Savoj J, Manekia K, Bangash M, Thakurta RG, Dang A, Vaziri ND, Singh B.

Pharmacol Res Perspect. 2018 Feb 19;6(2):e00385. doi: 10.1002/prp2.385. eCollection 2018 Apr.

35.

Increments in serum high-density lipoprotein cholesterol over time are not associated with improved outcomes in incident hemodialysis patients.

Chang TI, Streja E, Soohoo M, Ko GJ, Rhee CM, Kovesdy CP, Kashyap ML, Vaziri ND, Kalantar-Zadeh K, Moradi H.

J Clin Lipidol. 2018 Mar - Apr;12(2):488-497. doi: 10.1016/j.jacl.2018.01.010. Epub 2018 Jan 31.

36.

Novel RAS Inhibitors Poricoic Acid ZG and Poricoic Acid ZH Attenuate Renal Fibrosis via a Wnt/β-Catenin Pathway and Targeted Phosphorylation of smad3 Signaling.

Wang M, Chen DQ, Chen L, Liu D, Zhao H, Zhang ZH, Vaziri ND, Guo Y, Zhao YY, Cao G.

J Agric Food Chem. 2018 Feb 28;66(8):1828-1842. doi: 10.1021/acs.jafc.8b00099. Epub 2018 Feb 14.

PMID:
29383936
37.

LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease.

Suematsu Y, Jing W, Nunes A, Kashyap ML, Khazaeli M, Vaziri ND, Moradi H.

J Card Fail. 2018 Apr;24(4):266-275. doi: 10.1016/j.cardfail.2017.12.010. Epub 2018 Jan 8.

38.

LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD.

Jing W, Vaziri ND, Nunes A, Suematsu Y, Farzaneh T, Khazaeli M, Moradi H.

Am J Transl Res. 2017 Dec 15;9(12):5473-5484. eCollection 2017.

39.

Iatrogenic iron overload and its potential consequences in patients on hemodialysis.

Rostoker G, Vaziri ND.

Presse Med. 2017 Dec;46(12 Pt 2):e312-e328. doi: 10.1016/j.lpm.2017.10.014. Epub 2017 Nov 16. Review.

PMID:
29153377
40.

The Leaky Gut and Altered Microbiome in Chronic Kidney Disease.

Lau WL, Vaziri ND.

J Ren Nutr. 2017 Nov;27(6):458-461. doi: 10.1053/j.jrn.2017.02.010.

41.

Molecular mechanisms of disorders of lipid metabolism in chronic kidney disease.

Moradi H, Vaziri ND.

Front Biosci (Landmark Ed). 2018 Jan 1;23:146-161. Review.

PMID:
28930541
42.

Removal of uremic retention products by hemodialysis is coupled with indiscriminate loss of vital metabolites.

Zhang ZH, Mao JR, Chen H, Su W, Zhang Y, Zhang L, Chen DQ, Zhao YY, Vaziri ND.

Clin Biochem. 2017 Dec;50(18):1078-1086. doi: 10.1016/j.clinbiochem.2017.09.012. Epub 2017 Sep 18.

PMID:
28928007
43.

Increased Renal 2-Arachidonoylglycerol Level Is Associated with Improved Renal Function in a Mouse Model of Acute Kidney Injury.

Moradi H, Oveisi F, Khanifar E, Moreno-Sanz G, Vaziri ND, Piomelli D.

Cannabis Cannabinoid Res. 2016 Sep 1;1(1):218-228. doi: 10.1089/can.2016.0013. eCollection 2016.

44.

The nature, consequences, and management of neurological disorders in chronic kidney disease.

Jabbari B, Vaziri ND.

Hemodial Int. 2018 Apr;22(2):150-160. doi: 10.1111/hdi.12587. Epub 2017 Aug 11. Review.

45.

Treatment with dimethyl fumarate ameliorates liver ischemia/reperfusion injury.

Takasu C, Vaziri ND, Li S, Robles L, Vo K, Takasu M, Pham C, Farzaneh SH, Shimada M, Stamos MJ, Ichii H.

World J Gastroenterol. 2017 Jul 7;23(25):4508-4516. doi: 10.3748/wjg.v23.i25.4508.

46.

Risk of Postoperative Venous Thromboembolism Among Pregnant Women.

Suematsu Y, Obi Y, Shimomura A, Alizadeh RF, Vaziri ND, Nguyen NT, Stamos MJ, Ichii H.

Am J Cardiol. 2017 Aug 1;120(3):479-483. doi: 10.1016/j.amjcard.2017.04.053. Epub 2017 May 11.

47.

Role of RAS/Wnt/β-catenin axis activation in the pathogenesis of podocyte injury and tubulo-interstitial nephropathy.

Chen L, Chen DQ, Wang M, Liu D, Chen H, Dou F, Vaziri ND, Zhao YY.

Chem Biol Interact. 2017 Aug 1;273:56-72. doi: 10.1016/j.cbi.2017.05.025. Epub 2017 Jun 2.

PMID:
28578904
48.

Gene and protein expressions and metabolomics exhibit activated redox signaling and wnt/β-catenin pathway are associated with metabolite dysfunction in patients with chronic kidney disease.

Chen DQ, Cao G, Chen H, Liu D, Su W, Yu XY, Vaziri ND, Liu XH, Bai X, Zhang L, Zhao YY.

Redox Biol. 2017 Aug;12:505-521. doi: 10.1016/j.redox.2017.03.017. Epub 2017 Mar 23.

49.

The link between phenotype and fatty acid metabolism in advanced chronic kidney disease.

Chen DQ, Chen H, Chen L, Vaziri ND, Wang M, Li XR, Zhao YY.

Nephrol Dial Transplant. 2017 Jul 1;32(7):1154-1166. doi: 10.1093/ndt/gfw415.

PMID:
28339984
50.

Impact of iatrogenic iron overload on the course of hepatitis C in the dialysis population: A plea for caution.

Rostoker G, Vaziri ND.

Hemodial Int. 2017 Jun;21 Suppl 1:S68-S77. doi: 10.1111/hdi.12557. Epub 2017 Mar 23. Review.

PMID:
28332306

Supplemental Content

Loading ...
Support Center